Rabies Lab Safety Under Scrutiny: Rare Infections Expose Gaps in Biosafety Evidence

Rabies remains one of the most lethal infectious diseases known to medicine. Once clinical symptoms appear, viral encephalomyelitis caused by rabies virus and related lyssaviruses is almost invariably fatal, and the virus can pass from infected mammals to humans through contact with saliva or neural tissue. That extraordinary case fatality rate places unusual demands on the diagnostic and research laboratories that handle lyssavirus-infected materials every day, from brain tissue samples submitted for post-mortem confirmation to live virus stocks maintained for vaccine and antiviral research. A new review published in PLOS Neglected Tropical Diseases by Stuart D. Blacksell, Khanh Kim Le, Paola De Benedictis, and Morgane Gourlaouen now takes a critical look at how well current biosafety practices actually protect laboratory workers, and the authors conclude that the evidence base underpinning those practices is thinner than the stakes would suggest.

The review systematically examined the literature on biosafety risks associated with handling rabies virus and related lyssaviruses, focusing on three broad areas: the use of personal protective equipment, the procedures governing sample handling, and the chemical and physical methods available for inactivating virus before or during diagnostic work. The authors also paid particular attention to documented cases of laboratory-acquired rabies, treating these rare events as the most direct evidence of where protective systems have failed. Their assessment is not a rejection of existing practice, but a call to recognize that many widely adopted precautions rest on tradition and precautionary reasoning rather than on quantified risk data.

Laboratory-acquired rabies infections are, by any measure, rare. Yet the review emphasizes that their very rarity is part of the problem for biosafety science. Each documented case represents a failure mode that cannot be studied prospectively in any ethical way, and the small number of historical incidents makes it difficult to draw robust statistical conclusions about which exposures are most dangerous or which interventions are most effective. The cases that have occurred highlight important gaps in current biosafety practices, particularly around the handling of unfixed tissue, aerosol-generating procedures, and exposures that may not have been immediately recognized as high risk. For a disease with no curative treatment after symptom onset, even a single laboratory transmission event carries consequences that far exceed those of most occupational infections.

A central theme of the review is the striking variability in the effectiveness of disinfection and inactivation methods. Lyssaviruses are enveloped viruses and are generally considered susceptible to common disinfectants, including soap solutions, detergents, iodine preparations, and quaternary ammonium compounds, and to physical treatments such as heat. But the authors found that the evidence supporting these inactivation claims varies widely across studies, and that performance can degrade sharply in resource-limited settings where reagent quality, cold-chain reliability, and staff training may be inconsistent. A disinfection protocol validated in a well-equipped reference laboratory may not translate reliably to a district laboratory that lacks certified biosafety cabinets, reliable electricity, or access to validated chemical stocks.

This variability matters most at the diagnostic front line. The direct fluorescent antibody test, the gold standard for rabies diagnosis, requires processing fresh or frozen brain tissue, typically smearing the material onto slides and applying fluorescently labeled antibodies. The review notes that this and other key diagnostic procedures require validation under biosafety constraints, meaning that laboratories need evidence not only that the test performs accurately but that each step of sample preparation can be carried out with a well-characterized risk of exposure. In many settings, that validation has never been formally performed, leaving technicians to follow protocols inherited from other laboratories or adapted from general virology guidance without knowing whether the specific conditions of their workplace alter the risk profile.

The authors identify several significant knowledge gaps that they argue must be closed to make rabies biosafety genuinely evidence-based. The infectious dose for humans exposed to lyssavirus-contaminated materials in a laboratory context is not well established, which makes it impossible to define exposure thresholds or to calibrate protective measures against a quantitative risk. The effectiveness of decontamination methods, particularly under field and low-resource conditions, lacks standardized evaluation. And diagnostic standardization across laboratories remains incomplete, so that two facilities handling identical samples may follow substantially different procedures with different implicit assumptions about risk. Each of these gaps forces laboratories to err on the side of maximal caution, which is safe in principle but can be impractical, expensive, and in some cases counterproductive if it discourages testing.

The tension between precaution and practicality is especially acute in the regions where rabies burden is highest. Most human rabies deaths occur in Asia and Africa, where diagnostic capacity is often concentrated in a small number of national or regional reference laboratories. Strengthening biosafety in those laboratories is essential both to protect staff and to sustain the surveillance and confirmation testing on which rabies control programs depend. If biosafety requirements are specified at a level of infrastructure and cost that low-resource settings cannot meet, the practical effect may be to push diagnosis out of the laboratory altogether, relying on clinical suspicion rather than confirmation. The review argues that the solution is not to relax standards but to generate the evidence needed to specify which precautions are truly necessary for which procedures, so that resources can be targeted where they matter most.

Personal protective equipment features prominently in the review’s assessment of preventive measures. Gloves, gowns, eye protection, and respiratory protection are standard recommendations for work with potentially infectious lyssavirus materials, but the authors note that the evidence for specific combinations of equipment, and for the procedures by which equipment is donned and doffed, is limited. Sample handling procedures, including transport, storage, and the point at which a sample is considered inactivated, are similarly governed by a patchwork of institutional and national rules rather than by a shared, validated framework. Because lyssaviruses include not only classical rabies virus but a growing list of related species distributed across continents, protocols optimized for one virus or one region may not account for the properties of newly discovered lyssaviruses, adding another layer of uncertainty for laboratories that may encounter unfamiliar isolates.

The review’s conclusions point toward a concrete research agenda. Validating inactivation methods under realistic laboratory conditions, quantifying the stability of lyssaviruses in different matrices and environments, and standardizing diagnostic workflows with explicit biosafety checkpoints would all convert precautionary guidance into evidence-based protocols. The authors argue that strengthening such protocols is essential to ensure safer rabies diagnostics and to support effective rabies control, particularly in low-resource settings where the gap between written guidance and operational reality is widest. They also implicitly make the case that biosafety research deserves the same rigor as diagnostic or therapeutic research, with controlled evaluations, published validation data, and transparent reporting of failures and near-misses.

For a disease that kills tens of thousands of people each year, most of them in communities far from any laboratory, the connection between bench-side biosafety and global rabies control is direct. Diagnostic laboratories confirm suspected cases, monitor wildlife and dog populations, and verify the impact of vaccination campaigns; if those laboratories cannot operate safely and sustainably, the surveillance backbone of elimination programs weakens. The review by Blacksell and colleagues does not report a new outbreak or a new virus, but it addresses a quieter vulnerability: the possibility that the systems protecting the people who fight rabies are built on assumptions that have never been fully tested. Closing the knowledge gaps they identify, from infectious dose to decontamination efficacy, would give rabies laboratories everywhere a firmer foundation, and would help ensure that the drive to eliminate one of humanity’s oldest diseases does not place its own workforce at avoidable risk.

Subject of Research: Biosafety risks and precautions for handling rabies virus and related lyssaviruses in diagnostic and research laboratories

Article Title: Biosafety of rabies virus and related lyssaviruses: Risks, precautions, and knowledge gaps in diagnostic and research laboratories

Article References: Blacksell, S. D., Le, K. K., De Benedictis, P., & Gourlaouen, M. (2026). Biosafety of rabies virus and related lyssaviruses: Risks, precautions, and knowledge gaps in diagnostic and research laboratories. PLOS Neglected Tropical Diseases, 20(10), e0014757. https://doi.org/10.1371/journal.pntd.0014757

Image Credits: AI Generated

DOI: 10.1371/journal.pntd.0014757

Keywords: rabies, lyssavirus, biosafety, laboratory-acquired infection, direct fluorescent antibody test, virus inactivation, decontamination, diagnostic standardization, personal protective equipment, PLOS Neglected Tropical Diseases, resource-limited settings, occupational safety